Compare XPL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XPL | XGN |
|---|---|---|
| Founded | 1984 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.8M | 71.2M |
| IPO Year | 2000 | 2014 |
| Metric | XPL | XGN |
|---|---|---|
| Price | $0.79 | $4.67 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 7 |
| Target Price | $1.20 | ★ $8.86 |
| AVG Volume (30 Days) | 248.7K | ★ 401.9K |
| Earning Date | 05-04-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 42.86 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $8.12 |
| Revenue Next Year | N/A | $13.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.54 | $2.59 |
| 52 Week High | $0.98 | $12.23 |
| Indicator | XPL | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 44.62 | 57.89 |
| Support Level | $0.68 | $2.68 |
| Resistance Level | $0.81 | $5.55 |
| Average True Range (ATR) | 0.03 | 0.42 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 38.27 | 36.81 |
Solitario Resources Corp is an exploration company engaging in acquiring, exploring, and developing zinc properties and other precious metals in safe jurisdictions in North and South America. Its core mineral property assets are: the Florida Canyon zinc project in Peru, the Lik zinc project in Alaska, and the Golden Crest project in South Dakota. Additionally, Solitario holds an interest in the Chambara project in Peru and also has two early-stage projects, the Cat Creek project and the Bright Angel project in Colorado. The company is conducting mineral exploration on its Golden Crest project, the Cat Creek project, and the Bright Angel project on its own.
Exagen Inc is a medical technology company focused on the design, development and commercialization of diagnostic testing products under its AVISE brand. These products are used for the differential diagnosis, prognosis, and monitoring of rheumatic, autoimmune, and related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). The company operates in one operating segment. The majority of the company's revenue is derived from sales of its testing products.